U.S. PRODUCERS' QUESTIONNAIRE

SILICOMANGANESE FROM INDIA, KAZAKHSTAN, AND VENEZUELA

This questionnaire must be received by the Commission by no later than May 17, 2013

See page 4 of the Instruction Booklet for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its review of the antidumping duty orders concerning silicomanganese from India, Kazakhstan, and Venezuela (Inv. Nos. 731-TA-929-931 (Second Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).

Name of firm

City		Stat	te	Zip C	Code			
		s						
		omanganese (as defined in th						7?
□NO	(Sign the certifi	ication below and promptly reti	urn only thi	s page of th	ne questionnai	re to the Cor	mmission)	
		action booklet carefully, complete the Commission so as to be re-					entire	
		the U.S. Internationa						
on the followi	ng link. <u>nu</u>	ps://dropbox.usitc.gov/	OITIV/. (U	se the id	bilowing F	IIN: SIIVII	N)	
		CERTIFIC oplied in response to this que mation submitted is subject	uestionnai	re is comp				knowl
ief and understand ons of this certification provided in t ted by the Commiss	that the infor ation I also g his questionn sion on the san	oplied in response to this que mation submitted is subject grant consent for the Compaire and throughout this me or similar merchandise.	uestionnai t to audit d mission, d proceedin	re is comp and verific and its en g in any	cation by the nployees an other impo	e Commissi d contract rt-injury pi	on. personnel, roceedings	to use or rev
ief and understand ins of this certification provided in the ted by the Commission, its employee ining the records of	that the information I also good in the same submits, and contraft this proceeding are programs and the same same same same same same same sam	oplied in response to this que rmation submitted is subject grant consent for the Com- naire and throughout this me or similar merchandise. Atted in this questionnaire act personnel who are acting ing or related proceedings j and operations of the Comm	uestionnai t to audit d mission, d proceedin response response for which	re is compand verificand its en and its en g in any and throw capacity of this inforn	cation by the aployees an other impo ughout this of Commissi nation is su	e Commissi d contract rt-injury pr proceeding ion employ bmitted, or	on. personnel, roceedings may be u ees, for dev in internal	to use or rev sed by velopin audits
ief and understand ins of this certification provided in the ted by the Commission where the time information, its employee ining the records of the teleting to the seconds of the records of the record	that the information I also good in the same in this proceed in the same in th	oplied in response to this que rmation submitted is subject grant consent for the Com- naire and throughout this me or similar merchandise. Atted in this questionnaire act personnel who are acting ing or related proceedings j and operations of the Comm	uestionnai t to audit of proceeding response ng in the for which nission pu	re is compand verificand its en and its en g in any and throw capacity of this inforn	cation by the aployees an other impo ughout this of Commissi nation is su	e Commissi d contract rt-injury pr proceeding ion employ bmitted, or	on. personnel, roceedings may be u ees, for dev in internal	to use or rev sed by velopin audits
ief and understand ins of this certification provided in the ted by the Commission, its employee ining the records of the tersonnel will signal.	that the information I also good bis questionnation submiss, and contract this proceeding programs and non-disclossial	oplied in response to this question submitted is subject that consent for the Compaire and throughout this me or similar merchandise. It is the control of the control of the Compaire of the Compaire agreements.	uestionnai t to audit d mission, d proceedin response ng in the for which nission pu	re is compand verificand its en and its en and through capacity of this information	cation by the aployees an other imposing this of Commission is sure of U.S.C. A. Date	e Commissi d contract rt-injury pr proceeding ion employ bmitted, or	on. personnel, roceedings may be u ees, for dev in internal	to use or rev sed by velopin audits

PART I.—GENERAL INFORMATION

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

		hours	S	doll
	e interested in any comments yor the clarity of specific questi the above address.	•		
Establishments covered	LProvide the name and addre		* /	•
questionnaire (see page publicly traded, please s	pecify the stock exchange and			
publicly traded, please s Position regarding con		trading symbol.	e continuation of	Ethe
publicly traded, please s Position regarding con	ecify the stock exchange and	trading symbol.	e continuation of	the ttries?
Position regarding con antidumping duty order	inuation of orderDo you so currently in place for silicoman	upport or oppose	continuation of	The atries?

PART I.--GENERAL INFORMATION--Continued

Firm name		Address	Extent of owner
		<u></u>	
			have any related firms, either nganese from India, Kazakhsta
Venezuela into	the United Sta	tes or that are engaged in exp	orting silicomanganese from In
Kazakhstan, an	d Venezuela to	the United States?	
□ No	YesList	the following information.	
Firm name		Address	<u>Affiliation</u>
-			
			r firm have any related firms, e
			nganese from countries other that are engaged in exporting
			an, and Venezuela to the United
□ No	YesList	the following information.	
	country	<u>Address</u>	<u>Affiliation</u>
Firm name and	<u> </u>		

PART I.--GENERAL INFORMATION--Continued

□ No □	YesList the following information.	
Firm name	Address	<u>Affiliation</u>
	Parts II and IV of this questionnaire w	
business plan. Do	Parts II and IV of this questionnaire was your company or any related firm has cribe, discuss, or analyze expected massers. Please provide the requested documents, please expected documents, please expected.	ve a business plan or any interket conditions for silicomang cuments. If you are not provi
business plan. Doe documents that des	es your company or any related firm ha scribe, discuss, or analyze expected man YesPlease provide the requested door	ve a business plan or any interket conditions for silicomang cuments. If you are not provi
business plan. Doe documents that des	es your company or any related firm ha scribe, discuss, or analyze expected man YesPlease provide the requested door	ve a business plan or any interket conditions for silicomang cuments. If you are not provi

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Angela Newell (202-708-5409, angela.newell@usitc.gov). **Supply all data requested on a <u>calendar-year</u> basis**.

ı		
Title		
Email		
Telephone		
Fax		
changes in relation to the (check as many as app	ne production of	tte whether your firm has experienced any of the fold failicomanganese since January 1, 2007. (please describe)
plant closings		···
relocations		
expansions		
acquisitions		
		···
consolidations		
prolonged shutdo	owns or	
_	owns or	
_		

PART II.--TRADE AND RELATED INFORMATION--Continued

II-3.	<u>Anticipated changes in operations.</u> Does your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of silicomanganese in the future?							
	No YesSupply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation that address this issue. Include in your response a specific projection of your firm's capacity to produce silicomanganese (<i>in short tons</i>) for 2013 and 2014							
	stion II-4, if your response differs for particular orders, please indicate and explain the ar effect of revocation of specific orders.							
II-4.	Anticipated changes in operations in the event the order is revokedWould your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of silicomanganese in the future if the antidumping duty orders on silicomanganese from India, Kazakhstan, and Venezuela were to be revoked?							
	No YesSupply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation that address this issue. Include in your response a specific projection of your firm's capacity to produce silicomanganese (<i>in short tons</i>) for 2013 and 2014							
II-5.	Technology changes. —Have there been any significant changes in the technologies available fo the production of silicomanganese since the initial imposition of the antidumping duty orders?							
	□ No □ Yes—Please describe.							

PART II.--TRADE AND RELATED INFORMATION--Continued

II-6. <u>Furnace count and specs.</u>—Please detail your firms' furnaces and their specifications used in production of silicomanganese in the United States.

	Location (City, State)	Short description of furnace specifications (and if not operated throughout the period of review a discussion of the periods operated)	Dedicated to SiMn production (check = yes)	Year purchased, installed, or acquired (<i>year</i>)
1.				
2.				
3.				
4.				
5.				
6.				
7.				
8.				

More than eight.--Check here if your firm operated more than eight furnaces in the production of silicomanganese in the United States since January 1, 2007, and please provide the same information as requested in the above grid for those additional furnaces as an attachment to your firm's response to this questionnaire.

PART II.--TRADE AND RELATED INFORMATION--Continued

- II-7. **Product shifting.**—Please provide answers to each of the following questions relating to your firm's ability to shift production between silicomanganese and other products.
 - (a) In relation to those furnaces (reported in question II-6 above) not dedicated 100 percent to the production of silicomanganese, please provide the following information on the other products produced in those furnaces (if more than four products, list the largest).

Product	t(s)	Costs and tin	neframes in		witching	Est. share of furnace fleet's production time dedicated to product ¹ (share)
1. Ferromangar	nese					
2. Ferrosilicon						
3.						
4.						
hours of the all listed product i	l the furna n a given	ices reported in q	uestion II-6 (le, report 25	a.k.a., furna percent of	ace fleet) rela ferromangan	lal average total production ates to the production of the nese if in a year 500 hours
	Addition	nal discussion:				
(b)	producti		anese since J	anuary 1, 2	007, could th	dedicated 100 percent to the nese furnaces be converted
	☐ No		□ Y	esAnd at	t what cost/ti	ime constraint?

PART II.--TRADE AND RELATED INFORMATION--Continued

II-7.	<u>Produ</u>	ct shiftingC	ontinued							
	(c)	Does your firm own or operate furnaces not reported in question II-6 at all (<i>i.e.</i> , not involved in silicomanganese production during the period) that could be converted production of silicomanganese?								
		□ No			Yes	-And at wl	nat cost/ti	me constra	uint?	
silicon	ek and v	ll capacity.— weeks per year se at any time se report the fol) and in re since Janu	elation to clary 1, 200	only those 07 (i.e., rep	furnaces a	ctually us	sed to prod	luce	
				(Quanti	ity in short	t tons)				
					Y	ear			Januar	y-March
	Item	n Capacity ¹	2007	2008	2009	2010	2011	2012	2012	2013
Ferrori Ferrosi Other p	anganese langanese licon product 3	(from Q II-7a) (from Q II-7a)								
¹ The cicoman	verall pro ganese (a	duction capacity s reported in qu apacity quantity	estion II-6)	hou	rs per weel					
² All otl	ner produ	cts:	_•							
II-9.		raints on proc tion capacity.	luction	Please des	scribe the o	constraint(s) that set	the limit(s	s) on your	

PART II.--TRADE AND RELATED INFORMATION--Continued

II-10. <u>Trade data.</u>--Report your firm's production capacity, production, shipments, inventories, and employment related to the production of silicomanganese in your U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

	Quanti	ty (in snor	t tons) and	· ·	1,000)		1	
	Calendar year			-	y-March			
Average production capacity ¹ (quantity) (A)	2007	2008	2009	2010	2011	2012	2012	2013
Beginning-of-period inventories (quantity) (B)								
Production (quantity) (C)								
U.S. shipments: Commercial shipments: quantity (D)								
value (E)								
Internal consumption: ² quantity (F)								
value (G)								
Transfers to related firms: ² quantity (H)								
value (I)								
Export shipments: ³ quantity (J)								
value (K)								
End-of-period inventories (quantity) (L)								
Channels of distribution: U.S. shipments to distributors (quantity) (M)								
U.S. shipments to end users (quantity) (N)								
Employment data: Average number of PRWs (number) (O)								
Hours worked by PRWs (1,000 hours) (P)								
Wages paid to PRWs (value) (Q)								
¹ If your firm produces more tha equal the totality of all production as in question II-7) to the average prod	s reported i	n question	II-8), on wh	at basis did	your firm a	llocate over	rall capacity	(reported
² Are values of internal consumpursuant to Commission instruction transactions, please specify that bas at the value data reported in those I	? <mark>□ Yes</mark> sis (<i>e.g.</i> , co	☐ No	In the even	t that you us	se a differer	nt basis for	valuing thes	se
³ Identify your principal export m shipments reported (<i>i.e.</i> , Canada ap								t

PART II.--TRADE AND RELATED INFORMATION--Continued

II-11.	Recon	ciliation of trade data	
	(a)	Please note that the quantities is each period (<i>i.e.</i> , in each column	reported in question II-10 should reconcile as follows in in):
		$\frac{\text{Reconciliation}}{\text{B} + \text{C} - \text{D} - \text{F} - \text{H} - \text{J} = \text{L}}$	Do these data reconcile? ☐ Yes ☐ NoPlease explain
		D + F + H = M + N	Do these data reconcile? Yes NoPlease explain
	(b)	beginning-of-period inventorie	reported for end-of-period inventories should equal the streported in the subsequent calendar year (<i>i.e.</i> , line L of of year 2008). Do these data reconcile for each adjacent
		Yes. NoPl	ease explain.
	formul		transfers were priced at market value or by a non-market arketing rights to all transfers, and whether the related es other than your firm.
II-13.			97, has your firm been involved in a toll agreement (see garding the production of silicomanganese?
	☐ No	YesName firm(s)	•
II-14.	<u>FTZ</u>	Does your firm produce silicom	anganese in a foreign trade zone (FTZ)?
	☐ No	YesIdentify FTZ(s):
II-15.	Direct source		7, has your firm imported silicomanganese from any
	☐ No	Yes <u>COMPLETE</u> <u>QUESTION</u>	AND RETURN A U.S. IMPORTERS'

PART II.--TRADE AND RELATED INFORMATION--Continued

II-16.	<u>Purchases.</u> Other than direct imports, has your firm otherwise purchased silicomanganese since January 1, 2007? (See definitions in the instruction booklet.)										
		e, please		te) and r	eport the	e quantit		easons d lue of su			
	Reasons:										
	(Quan	tity <i>in sl</i>	nort tons,	, value <i>in</i>	\$1,000)						
				Calend	lar year			January	y-March		
	Item	2007	2008	2009	2010	2011	2012	2012	2013		
	value										
Ka	zakhstan: <i>quantity</i>										
	value										
Ve	nezuela: <i>quantity</i>										
	value										
All	other countries: quantity										
	value										
PROD	HASES FROM DOMESTIC UCERS: ² antity										
vai	lue										
FOR V	HASES FROM OTHER SOURCES VHICH COUNTRY OF ORGIN IS OWN: ³ antity										
Va	lue										
¹ P source	lease list the name of the importer(s), please identify the source for each li	from whi sted sup	ch you pu plier.	irchased	this prod	uct. If you	ur supplie	rs differ b	У		
² P	lease list the name of the domestic pr	oducer(s	s) from wh	nich you p	ourchased	d this prod	duct.				
3 P	lease list the name of the other sourc	es from \	which you	purchase	ed this pr	oduct.			<u> </u>		

PART II.--TRADE AND RELATED INFORMATION--Continued

For questions II-17 and II-18, if your response differs for particular orders, please indicate and explain the particular effect of imposition and/or revocation of specific orders.

pro co va	oduction ca sts, profits, lues relatin	of revocation of the order bacity, production, U.S. shi cash flow, capital expendit to the production of silico anese from India, Kazakhs	pments, inventories ures, research and d manganese in the fu	, purchases, employmevelopment expendituture if the antidumping	nent, revenu ures, or ass
	No	business plans	nderlying assumptio	e, and significance of ns, along with relevan documentation for an	nt portions

PART III.--FINANCIAL INFORMATION

	Name		
L	Title		
	Email		
L	Teleph	one	
L	Fax		
	Accou	nting sy	stemBriefly describe your financial accounting system.
	A.	When o	does your fiscal year end (month and day)?
			fiscal year changed during the period examined, explain below:
	B.1.		be the lowest level of operations (e.g., plant, division, company-wide) for which al statements are prepared that include silicomanganese:
	2.		our firm prepare profit/loss statements for silicomanganese:
	3.	Yes	S No ften did your firm (or parent company) prepare financial statements (including
	۶.	annual	reports, 10Ks)? Please check relevant items below.
			dited, unaudited, annual reports, 10Ks, 10 Qs,
			nthly, quarterly, semi-annually, annually
	4.		nting basis: GAAP, cash, tax, or other comprehensive basis bunting (specify)
		includir silicomo	The Commission may request that your company submit copies of its financial statements, ag internal profit-and-loss statements for the division or product group that includes anganese, as well as those statements and worksheets used to compile data for your firm's annaire response.
		ccounting cost, etc.)	ng systemBriefly describe your cost accounting system (e.g., standard cost, job).
			isBriefly describe your allocation basis, if any, for COGS, SG&A, and interest

PART III.--FINANCIAL INFORMATION--Continued

III-5.	produced silic	etsPlease list any other produced omanganese, and provide the sour most recent fiscal year:			
	Products			Share of	<u>sales</u>
					%
					%
					%
					%
					%
III-6.	production of	m purchase inputs (raw materi silicomanganese <u>from any rela</u> inue to question III-7 below.	ited firms?	·	
III-7.		related firmsIn the space pr silicomanganese that your firm			
	<u>Input</u>		<u>R</u>	elated party	
III-8.	parties should costs reported associated pro	related firms at costAll interests be eliminated from the costs r in question III-10 should only fit component). Reasonable must be in the component on inputs purchased from relationships.	eported to the Cor reflect the related nethods for determ	mmission in q I party's cost nining and elim	question III-10 (i.e., and not include an
	•	complied with the Commissionsed from related parties?	on's instructions re	egarding costs	s associated with
	Yes	☐ NoPlease contact Justin	n Jee (202-205-31	86, Justin.jee	@usitc.gov).

PART III.--FINANCIAL INFORMATION--Continued

III-9. Nonrecurring items (charges and gains) included in reported in silicomanganese financial results.--For each annual and interim period for which financial results are reported in question III-10, please specify all material (significant) nonrecurring items (charges and gains) in the schedule below, the specific table III-10 line item where the nonrecurring items are included, a brief description of the relevant nonrecurring items, and the associated values (in \$1,000), as reflected in table III-10; i.e., if an aggregate nonrecurring item has been allocated to table III-10, only the allocated value amount included in table III-10 should be reported in the schedule below. Note: The Commission's objective here is to gather information only on material (significant) nonrecurring items which impacted the reported silicomanganese financial results in table III-10.

			Fiscal yea	rs ended			January	/-March
	2007	2008	2009	2010	2011	2012	2012	2013
Nonrecurring item: In this column please provide a brief description of each nonrecurring item and indicate the specific table III-10 line item where the nonrecurring item is included.		ring item: I			report the a	amount (<i>in \$</i>	1,000) of the	e relevant
1.								
2.								
3.								
4.								
5.								
6.								
7.								

PART III.--FINANCIAL INFORMATION--Continued

III-10. Operations on silicomanganese.--Report the revenue and related cost information requested below on the silicomanganese operations of your U.S. establishment(s). Do not report resales of products. Note that internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost. Provide data for your six most recently completed fiscal years in chronological order from left to right, and for the specified interim periods. If your firm was involved in tolling operations (either as the toller or as the tollee), please contact Justin Jee at (202) 205-3186 before completing this section of the questionnaire.

Quantity	(in short tor	s) and valu		<u>'</u>		
			Fiscal yea	rs ended		
Item	2007	2008	2009	2010	2011	2012
Net sales quantities: ³ Commercial sales ("CS")						
Internal consumption ("IC")						
Transfers to related firms ("Transfers")						
Total net sales quantities						
Net sales values: ³ Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales values						
Cost of goods sold (COGS): ⁴ Raw materials						
Direct labor						
Other factory costs						
Total COGS						
Gross profit or (loss)						
Selling, general, and administrative (SG&A) expenses: Selling expenses						
General and administrative expenses						
Total SG&A expenses						
Operating income (loss)						
Other income and expenses: Interest expense						
All other expense items						
All other income items						
All other income or expenses, net						
Net income or (loss) before income taxes						
Depreciation/amortization included above						

¹ Include only sales (whether domestic or export) and costs related to your <u>U.S. manufacturing operations</u>.

² Please eliminate any profits or (losses) on inputs from related firms pursuant question III-8.

³ Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

⁴ COGS should include costs associated with CS, IC, and Transfers, as well as export shipments in question II-8.

PART III.--FINANCIAL INFORMATION--Continued

III-10. Operations on silicomanganese.--Continued

Quantity (in she	ort tons) and value (in \$1,000)	
Item	January-March 2012	January-March 2013
Net sales quantities: ³		
Commercial sales		
Internal consumption		
Transfers to related firms		
Total net sales quantities		
Net sales values: ³ Commercial sales		
Internal consumption		
Transfers to related firms		
Total net sales values		
Cost of goods sold (COGS): ⁴ Raw materials		
Direct labor		
Other factory costs		
Total COGS		
Gross profit or (loss)		
Selling, general, and administrative (SG&A) expenses: Selling expenses		
General and administrative expenses		
Total SG&A expenses		
Operating income (loss)		
Other income and expenses: Interest expense		
All other expense items		
All other income items		
All other income or expenses, net		
Net income or (loss) before income taxes		
Depreciation/amortization included above		
1		

Include only sales (whether <u>domestic or export</u>) and costs related to your <u>U.S. manufacturing operations</u>.

Please <u>eliminate any profits or (losses) on inputs from related firms</u> pursuant question III-8.

Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

COGS should include costs associated with CS, IC, and Transfers, as well as export shipments in question II-8.

PART III.--FINANCIAL INFORMATION--Continued

III-11. <u>Asset values</u>.--Report the <u>total</u> assets (i.e., both current and long-term assets) associated with the production, warehousing, and sale of silicomanganese. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for silicomanganese in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with your cost allocations in the previous question. Provide data as of the end of your six most recently completed fiscal years in chronological order from left to right.

Note: Total assets should reflect <u>net assets</u> after any accumulated depreciation and allowances deducted. Total assets should be <u>allocated to the subject products</u> if these assets are also related to other products. Please provide a <u>brief explanation if there are any substantial changes</u> in total asset value during the period; e.g., due to asset write-offs, revaluation, and major purchases.

			Value (ii	n \$1,000)		
			Fiscal yea	rs ended		
Item	2007	2008	2009	2010	2011	2012
Total assets (net)						

III-12. <u>Capital expenditures and research and development expenses</u>.--Report your firm's capital expenditures and research and development expenses on silicomanganese. Provide data for your six most recently completed fiscal years in chronological order from left to right, and for the specified interim periods.

	_			Value (<i>ii</i>	n \$1,000)			
			Fiscal yea	ırs ended			Januar	y-March
Item	2007	2008	2009	2010	2011	2012	2012	2013
Capital expenditures								
Research and development expenses								

III-13.	<u>Data consistency and reconciliationPlease indicate whether your financial data for questions</u>
	III-10, 11, and 12 are based on a calendar year or your fiscal year:
	Calendar year Fiscal year (specify)
	Please note the quantities and values reported in question III-10 should reconcile with the data reported in question II-10 (including export shipments) as long as they are reported on the same calendar year basis.
	Do these data in question III-10 reconcile with data in question II-10?
	Yes NoPlease explain

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Samantha Day (202-205-2088, Samantha.Day@usitc.gov)

<u>Contact information</u>.-- Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part IV.

Name	
Title	
Email	
Telephone	
Fax	

PRICE DATA

IV-1. This question requests quarterly quantity and value data, f.o.b. your U.S. point of shipment, for your commercial shipments to unrelated U.S. customers since 2007 of the following products produced by your firm.

<u>Product 1</u>.—ASTM grade B bulk silicomanganese sold to steel producers under quarterly requirement contracts

<u>Product 2</u>.—ASTM grade B bulk silicomanganese sold to steel producers as spot sales

Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include U.S.-inland transportation costs. Total dollar values should reflect the *final net* amount paid to you (i.e., should be net of all deductions for discounts or rebates). See instruction booklet.

PART IV.--PRICING AND MARKET FACTORS--Continued

IV-1. <u>Pricing data.</u>--Report below the quarterly price data¹ for pricing products² produced and sold by your firm. Please note that value is requested in ACTUAL DOLLARS not \$1,000s dollars.

	(Quantity i	n short tons, value	in dollars)	
		duct 1		duct 2
Period of shipment	Quantity	Value	Quantity	Value
2007:			-	
January-March				
April-June				
July-September				
October-December				
2008:				
January-March				
April-June				
July-September				
October-December				
2009:				
January-March				
April-June				
July-September				
October-December				
2010:				
January-March				
April-June				
July-September				
October-December				
2011:				
January-March				
April-June				
July-September				
October-December				
2012:				
January-March				
April-June				
July-September				
October-December				
2013:				
January-March				
¹ Net values (<i>i.e.</i> , gross returned goods), f.o.b. your ² Pricing product defini	U.S. point of shipmer	nt.	es, rebates, prepaid freigl t IV.	nt, and the value of
NoteIf your product does provide a description of you				
Product 1:				
Product 2:	·			

PART IV.--PRICING AND MARKET FACTORS--Continued

Transact by transact		Set price lists	Other	If othe	r, describe
Discount apply).	oolicy Please	indicate and	d describe y	our firm's discount po	olicies (check all the
Quantit discoun		No discount policy	Other	D	escribe
(b) O	ı what basis are	your prices	of U.Spro	oduced silicomangane	se usually quoted (a
	(e)?				
		F.o.b.	If f.o.b.,	specify point	
	e)?	F.o.b.	If f.o.b.,	specify point	
On Contract	Delivered versus spot Aganese in 2012 velse basis?	□ Approximate	ely what sha	are of your firm's sales contract basis, (2) show	t-term contract bas
Contract silicomans	Delivered versus spot Aganese in 2012	□ Approximate	ely what sha	are of your firm's sales contract basis, (2) show	rt-term contract bas
Contract silicomans	versus spot Aganese in 2012 sles basis? Type of sale Long-term co than 12 months	Approximate was on a (1) ntracts (mults)	ely what sha long-term o	are of your firm's sales contract basis, (2) showing the sales of the	t-term contract bas
Contract silicomans	Delivered versus spot Aganese in 2012 seles basis? Type of sale Long-term co	Approximate was on a (1) ntracts (multiple)	ely what sha long-term o	are of your firm's sales contract basis, (2) showing the sales of the	rt-term contract bas are of 2 sales

Total

100

%

PART IV.--PRICING AND MARKET FACTORS--Continued

IV-6. <u>Contract provisions.</u>— Please fill out the table with respect to provisions of your typical sales contracts for silicomanganese (or check "not applicable" if your firm does not sell on a long-term and/or short-term contract basis).

Typical sales contract provisions	Item	Short-term contracts (multiple deliveries up to and including 12 months)	Long-term contracts (multiple deliveries for more than 12 months)
Average contract duration	Number of days		
Price renegotiation (during the	Yes		
contract period)	No		
	Quantity		
Fixed quantity and/or price	Price		
	Both		
Most or release provision	Yes		
Meet or release provision	No		
Not applicable			

IV-7. <u>Lead times.</u>--What is the average lead time between a customer's order and the date of delivery for your firm's sales of your U.S.-produced silicomanganese?

Source	Share of 2012 sales	Lead time (days)
From inventory	%	
Produced to order	%	
Total	100 %	

IV-8. Shipping information.--

- (a) What is the approximate percentage of the total delivered cost of silicomanganese that is accounted for by U.S. inland transportation costs? ______ %
- (b) Who generally arranges the transportation to your customers' locations?
 ☐ your firm ☐ purchaser (check one)
- (c) Indicate the approximate percentage of your sales of silicomanganese that are delivered the following distances from your production facility.

Distance from production facility	Share	
Within 100 miles		%
101 to 1,000 miles		%
Over 1,000 miles		%
Total	100	%

PART IV.--PRICING AND MARKET FACTORS--Continued

IV-9. <u>Geographical shipments.--</u> What is the geographic market area in the United States served by your firm's silicomanganese? (check all that apply)

Geographic area	if applicable
NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT.	
MidwestIL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	
SoutheastAL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	
Central SouthwestAR, LA, OK, and TX.	
MountainsAZ, CO, ID, MT, NV, NM, UT, and WY.	
Pacific CoastCA, OR, and WA.	
Other .—All other markets in the United States not previously listed, including AK, HI, PR, and VI, among others.	

IV-10. <u>End uses.</u>--List the end uses of the silicomanganese that you manufacture. For each end-use product, what percentage of the <u>total cost</u> is accounted for by silicomanganese and other inputs?

	Share of total cost accounted		
End use product	Silicomanganese (percent)	Other inputs (percent)	Total
Steel (integrated mill)	%	%	100%
Steel (electric arc furnace)	%	%	100%
Other (specify):	%	%	100%

IV-11. <u>Changes in end uses.</u>—Have there been any changes in the end uses of silicomanganese since 2007? Do you anticipate any future changes?

Changes in end uses	No	Yes	Explain
Changes since 2007			
Anticipated changes			

		F	nd us	e in which this			nges in the prices of this substituted the price for silicomanganese?
S	Substitute	substitute is used		No Ye	Yes	Explanation	
	Changes in substitutes	No	Yes				Explain
Γ	Oh an see a lee						
		No	Yes				Explain
	substitutes	No	Yes				Explain
		No	Yes				Explain
<u>.</u>	substitutes Changes since	No	Yes				Explain
	changes since 2007 Anticipated changes		Yes				Explain
14. <u>I</u>	substitutes Changes since 2007 Anticipated changes Raw materials. (a) To what e	xtent	have o	changes in the pricanese since 2007?	es of 1	aw m	Explain aterials affected your firm's selling
14. <u>I</u>	substitutes Changes since 2007 Anticipated changes Raw materials. a) To what e prices for	xtent	have o	anese since 2007?			aterials affected your firm's selling
-14. <u>I</u>	substitutes Changes since 2007 Anticipated changes Raw materials. a) To what e prices for	xtent	have o	anese since 2007?			

IV-15.	supply product product	es in factors affecting supplyHave any changes occurred in any other factors affecting (e.g., changes in availability or prices of energy or labor; transportation conditions; cion capacity and/or methods of production; technology; export markets; or alternative cion opportunities) that affected the availability of U.Sproduced silicomanganese in the arket since 2007?
	□ No	YesPlease note the time period(s) of any such changes, the factors(s) involved, and the impact such changes had on your shipment volumes and prices.
IV-16.		bility of supply (U.Sproduced)
1, 10.	(a)	Do you anticipate any changes in terms of the availability of U.Sproduced silicomanganese in the U.S. market in the future?
		☐ Increase ☐ No change ☐ Decrease
	(b)	If you anticipate changes in supply, please explain.
IV-17.	(<i>i.e.</i> , sil	bility of supply (nonsubject)Has the availability of NONSUBJECT silicomanganese icomanganese imported from countries other than India, Kazakhstan, and Venezuela) d since 2007?
	□ No	YesPlease explain.

aantmaata a	han aal	nark				•	t record d offeet record films, a chility to
			_				t would affect your firm's ability to ntry markets within a 12-month
period.							·
-							
							es in the product range, product mix,
or marketin	g of sil	icon	nanga	inese si	ince 2007?	Do you antic	ipate any future changes?
Change							
product m							
marketi		No	Yes				Explain
Changes s 2007	nce						
Anticipated changes Demand tr		Ind	icate	how do	emand withi	n the United	States and outside of the United Stat
Demand tr (if known) to demand will	ends for silic	oma ge in	ngan the f	ese has uture.	s changed sin	nce January e principal fa	States and outside of the United Stat 1, 2007, and how you anticipate ctors that have affected, and that you
Demand tr (if known) to demand will	ends for silic	coma ge in ct, tl	the f	ese has uture.	s changed sin Describe the	nce January e principal fa	1, 2007, and how you anticipate
Demand tr (if known) to demand will anticipate w	ends for silic chang ill affe	coma ge in ct, tl	the f	uture. change	Describe the sin demand	nce January e principal fa	1, 2007, and how you anticipate ctors that have affected, and that you Factors
Demand tr (if known) to demand will anticipate w	ends or silic chang ill affe	coma ge in ct, tl	the f	uture. change	Describe the sin demand	nce January e principal fa Fluctuate	1, 2007, and how you anticipate ctors that have affected, and that you Factors
Demand tr (if known) to demand will anticipate w Market Within the United	ends or silic chang ill affe	comage in ct, the	the f	uture. change	Describe the s in demand Decrease Dema	nce January e principal fa Fluctuate	1, 2007, and how you anticipate ctors that have affected, and that you Factors
Demand tr (if known) idemand will anticipate w Market Within the United States Outside the United	ends or silic chang ill affe	eomage in ect, the	the f	uture. change	Decrease Dema	Fluctuate	1, 2007, and how you anticipate ctors that have affected, and that you Factors
Demand tr (if known) idemand will anticipate w Market Within the United States Outside the United	ends or silic chang ill affe	eomage in ect, the	the f	uture. change	Decrease Dema	Fluctuate	1, 2007, and how you anticipate ctors that have affected, and that you Factors

	(a) Is the silicomanganese market subject to business cycles or conditions of competition (including seasonal business) distinctive to silicomanganese?
	☐ No (skip to question IV-22.) ☐ Yes Please describe and then answer part (b).
	(b) If yes, have there been any changes in the business cycles or conditions of competition for silicomanganese since January 1, 2007?
	☐ No ☐ Yes Please describe.
22.	Price comparisonsPlease compare market prices of silicomanganese in U.S. and non-U.S. markets, if known. Provide specific information as to time periods and regions for any price comparisons.
23.	Market studiesPlease provide as a separate attachment to this request any studies, surveys, etc. that you are aware of that quantify and/or otherwise discuss silicomanganese supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including India, Kazakhstan, and Venezuela, and (3) the world as a whole. Of particular interest are such data from 2007 to the present and forecasts for the future.
	that you are aware of that quantify and/or otherwise discuss silicomanganese supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including India, Kazakhstan, and Venezuela, and (3) the world as a whole. Of particular interest are such data from 2007 to the present and forecasts

PART IV.--PRICING AND MARKET FACTORS--Continued

IV-25. <u>Interchangeability.</u>--Is silicomanganese produced in the United States and in other countries interchangeable (*i.e.*, can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

A = the products from a specified country-pair are *always* interchangeable

F = the products are *frequently* interchangeable

S = the products are *sometimes* interchangeable

N = the products are *never* interchangeable

0 = no familiarity with products from a specified country-pair

Country-pair	India	Kazakhstan	Venezuela	Other countries
United States				
India				
Kazakhstan				
Venezuela				
	r-pair producing silice the factors that limit o			interchangeable,

PART IV.--PRICING AND MARKET FACTORS--Continued

IV-26. <u>Factors other than price</u>.--Are differences other than price (*i.e.*, quality, availability, transportation network, product range, technical support, *etc*.) between silicomanganese produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N =such differences are *never* significant

0 = no familiarity with products from a specified country-pair

Country-pair	India	Kazakhstan	Venezuela	Other countries
United States				
India				
Kazakhstan				
Venezuela				
factor in your fir	r-pair for which factor m's sales of silicoma disadvantages impar	anganese, identify th		